The FDA has on 1 May 2013, approved the prescription medication Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) from Shire ,as a...
Shire will initiate two Phase IV clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta� (methylphenidate HCl) Extended-Release...
Shire plc has announced positive top-line results from two identically designed randomized placebo-controlled Phase III studies evaluating the efficacy and...
The FDA has accepted the filing for review of a supplemental New Drug Application (sNDA) for Vyvanse (lisdexamfetamine dimesylate) Capsules,...
A study to evaluate the safety and efficacy of Vyvanse(lisdexamfetamine dimesylate) Capsules 30, 50 or 70 mg compared to placebo...
Shire plc announced top-line results from two pivotal Phase III investigational studies evaluating the efficacy and safety of Vyvanse (lisdexamfetamine...
Results from a Phase III extension study of Vyvanse (lisdexamfetamine dimesylate), from Shire, show that after 6 months of treatment,...
Shire plc has announced that the FDA approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the...
Shire plc reported positive top-line results from a 39-week, long-term maintenance of efficacy study of Vyvanse (lisdexamfetamine dimesylate) Capsules (CII)...
A Phase IIIb study comparing the efficacy and safety of the Attention Deficit Hyperactivity Disorder (ADHD) treatments shows Vyvanse/Elvanse (lisdexamfetamine...